Navigation Links
Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
Date:3/11/2011

CAMBRIDGE, Mass. and LONDON, March 11, 2011 /PRNewswire/ -- Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.  

Following preliminary review of the data, no new or unexpected treatment-related safety concerns have emerged during the DEFEND-1 study. Study investigators and regulatory agencies have been notified of the DEFEND-1 study outcome.

GSK will continue to explore additional dosing regimens to inform decisions about the future clinical development programme for otelixizumab.  New recruitment and dosing in the DEFEND-2 study, the ongoing confirmatory Phase 3 study with a design similar to DEFEND-1, has been suspended pending review of the DEFEND-1 results.

"While we are disappointed in the DEFEND-1 results of otelixizumab, we remain committed to the development and commercialization of the candidates in our pipeline, each of which has a distinct mechanism and target for correcting abnormal immune responses," said Douglas J. Ringler, VMD, President and Chief Executive Officer of Tolerx. "Our immunotherapy candidates represent some of the latest scientific advances in harnessing the immune system for therapeutic benefit, including TRX518 which is a showpiece of our pipeline as an immunotherapy to treat cancer."

"Clearly these are disappointing data, but we are committed to working with Tolerx to better understand the results of this study and determine the way forward," said Jackie Parkin, Medicines Development Leader, GlaxoSmithKline.

Tolerx Pipeline

In addition to otelixizumab, Tolerx has four product candidates in various stages of development, and each candidate is based on Tolerx's immunology expertise in understanding how therapies can be designed
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
2. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
3. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
4. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
5. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
6. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
7. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
8. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
9. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
10. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
11. GlaxoSmithKline Wins Environmental Stewardship Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  ResMed Inc. (NYSE: RMD ... 30, 2015.  Revenue for the quarter was $453.1 million, ... June 30, 2014 (a 17 percent increase on a ... with the quarter ended June 30, 2014.  Diluted earnings ... the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... and VANCOUVER , July 30, 2015 ... today that it will report its second quarter 2015 ... will host a conference call and live webcast at ... financial results, clinical development programs and a general corporate ... on to the Investor Relations page of the OncoGenex ...
(Date:7/30/2015)... , July 30, 2015  Cleveland Clinic President ... 2015 keynote address last month that industry is compelled ... order to gain the efficiencies—and develop the transformational innovations ... Dr. Barsoum,s comments were preceded by Doug Kohrs ... and OMTEC moderator, who stressed that industry must add ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... HAMBURG , Feb. 3 , The International ... a global teleconference that will: , Detail the launch of ... its symposium in Hamburg being held February 5-6, ... develop a comprehensive, evidence-based consensus on the use of NPWT; ...
... BALTIMORE , Feb. 2 Celsis In Vitro, Inc. ... lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical ... District of Illinois in Chicago .  XenoTech and ... that certain processes and methods performed by XenoTech associated with its ...
Cached Medicine Technology:The International Negative Pressure Wound Therapy Expert Panel to Announce Results of Inaugural Symposium in Hamburg 2Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 2Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 3
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... In an ... are hospitalized, Dr. Aggarwal is making a change in his practice. , The decision ... Effective August 14, 2015, Dr. Aggarwal will be transferring his in-patient admissions to the ...
(Date:7/30/2015)... NY (PRWEB) , ... July 30, 2015 , ... ... and Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the ... Chewable as a simple way to get the natural ingredients that may help ...
(Date:7/30/2015)... MD (PRWEB) , ... July 30, 2015 , ... ... serving the Mid-Atlantic region, is the recipient of three awards in the Service ... for communications programs created for Choptank Transport, KRM Development Corporation and University of ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... been consistently growing into one of the largest, family-owned low cost service and ... residential and commercial applications, as well as growing their company to meet the ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a high-quality ... Bernardino, recently announced that the Centers for Medicare and Medicaid (CMS) have awarded its ... care providers. 24/7 Care At Home’s agency is one of three top Orange County ...
Breaking Medicine News(10 mins):Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2
... an apology after a diabetic man who suffered a burnt ... with a misdiagnosis of gangrene.// Derek Atkinson, 56, from Newton ... consultant at Bishop Auckland General Hospital. ,In November ... and since the symptoms seemed very much like the previous ...
... increasing exponentially in over-50s in Scotland causing widespread concern. ... diseases had more than trebled in this segment of ... are also rising rapidly in senior citizens in Scotland. ... safe sex message. ,The rise in infections ...
... E D Marak, who was hospitalised here yesterday with ... ,'Marak's temparature has now become normal, so ... of state-run civil hospital Dr B Garod told PTI ... and symptoms of Malaria after returning from a visit ...
... Pradesh government Tuesday ascribed the increase in the number of ... year - to an increase in the number of HIV ... by Congress legislators Sajjan Singh Verma and Govind Singh, on ... Minister Ajay Vishnoi said: "The number of HIV test centres ...
... and other tobacco products will carry a sign of a ... packets from Feb 1, 2007, the health ministry// said Tuesday. ... product must bear a skull-and-bones sign, a health warning saying ... effects of tobacco use and a health message. ...
... HIV/AIDS, a Community Based Organisation (CBO) was launched here ... Initiative Roots) would bring together hundreds of transgenders from ... at empowering and enabling the community to undertake and ... vision of the newly formed collective was to ensure ...
Cached Medicine News:
... Mini-TrueView Arthroscopes,Based on the TrueView II design, ... optic telescopes for small joint arthroscopy is ... autoclavable and very durable thanks to Olympus ... new telescope class means bright images, brilliant ...
... to provide excellent protection and ease of ... being closer to an adhesive in molecular ... CoEase to maintain viscosity at high shear ... worlds for superb performance during capsulorhexis, phaco, ...
151 channels cover the entire head with a high density, with provisions for the eyes and ears. Patients and subjects are examined in a comfortable seated position or laying down....
... for evaluating a wide range of functions of ... Often referred to at the "whole body" MSI ... spinal cord and peripheral nerve studies, are expanding ... detector coils, covers a circular area approximately 32 ...
Medicine Products: